



Supplementary Figure 1. Activation and proliferation of CD8 T cells after TNF blockade with TNFR blocking antibodies. PBMCs from healthy donors were activated with plate-bound anti-CD3 and soluble anti-CD28 mAbs for seven days in the presence or absence of selective blocking antibodies against TNFR1 or TNFR2. Flow cytometry assessment of surface expression of CD25 (A) and PD-1 (B) (n=12) on FACS-gated CD8 T cells. C, supernatants from the cultures set up in the presence or absence of blocking antibodies against TNFR1 and TNFR2 were analyzed to determine the concentration of soluble IFN- γ levels (n=7). D, intracellular levels of Granzyme B (n=8) in FACS-gated CD8 T cells. E, real-time lysis of HCT116 tumor cells when cultured with CD8 T cells and anti-CD3-Epcam BiTE, in the presence or absence of selectively blocking antibodies against TNFR1 or TNFR2. Impedance-based tumor-cell cytotoxicity was performed in duplicate wells. F, flow cytometry assessment of intracellular levels of Ki67 (n=8) in FACS-gated CD8 T cells.